Search results
Results From The WOW.Com Content Network
Novartis plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs.
Alcon is a public company that produces ophthalmic products, such as contact lenses, surgical devices and pharmaceuticals. It was founded in 1945 in Texas, USA, and became a subsidiary of Novartis in 2010, before spinning off in 2019.
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.
Novartis is one of the largest pharmaceutical companies in the world, formed in 1996 by the merger of Ciba-Geigy and Sandoz. It produces drugs, vaccines, diagnostics, and other products, and has a history of acquisitions, spinoffs, and controversies.
Spin-off entity Transaction value (in billions USD) Inflation adjusted (in billions 2022 USD) Ref 1 2024 General Electric Company: GE Aerospace, GE Vernova, GE Healthcare: 191 191 [1] 2 2008 Altria Group: Philip Morris International: 108 141 [2] [3] 3 2000 BCE: Nortel: 60 97 [3] 4 2013 Abbott Laboratories: AbbVie: 56 67 [3] 5 2015 eBay: PayPal ...
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs. Pharma Stock Roundup: NVS to Divest Eye Care Unit ...
AbbVie is a spin-off of Abbott Laboratories that produces Humira, Botox, Imbruvica, and other drugs. It has a history of acquisitions, collaborations, and patent disputes in the pharmaceutical industry.